Advertisement
UK markets close in 59 minutes
  • FTSE 100

    8,200.19
    +35.29 (+0.43%)
     
  • FTSE 250

    21,093.88
    -119.91 (-0.57%)
     
  • AIM

    786.70
    -0.28 (-0.04%)
     
  • GBP/EUR

    1.1905
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.3022
    +0.0049 (+0.38%)
     
  • Bitcoin GBP

    49,817.38
    +951.97 (+1.95%)
     
  • CMC Crypto 200

    1,346.67
    +4.35 (+0.32%)
     
  • S&P 500

    5,604.49
    -62.71 (-1.11%)
     
  • DOW

    41,103.39
    +148.91 (+0.36%)
     
  • CRUDE OIL

    82.16
    +1.40 (+1.73%)
     
  • GOLD FUTURES

    2,475.60
    +7.80 (+0.32%)
     
  • NIKKEI 225

    41,097.69
    -177.39 (-0.43%)
     
  • HANG SENG

    17,739.41
    +11.43 (+0.06%)
     
  • DAX

    18,483.83
    -34.20 (-0.18%)
     
  • CAC 40

    7,590.78
    +10.75 (+0.14%)
     

Should You Investigate DENTSPLY SIRONA Inc. (NASDAQ:XRAY) At US$26.11?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY), might not be a large cap stock, but it saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$34.13 and falling to the lows of US$26.11. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether DENTSPLY SIRONA's current trading price of US$26.11 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at DENTSPLY SIRONA’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for DENTSPLY SIRONA

What Is DENTSPLY SIRONA Worth?

Good news, investors! DENTSPLY SIRONA is still a bargain right now. According to our valuation, the intrinsic value for the stock is $35.84, but it is currently trading at US$26.11 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, DENTSPLY SIRONA’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What kind of growth will DENTSPLY SIRONA generate?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Though in the case of DENTSPLY SIRONA, it is expected to deliver a relatively unexciting top-line growth of 9.2% in the next few years, which doesn’t help build up its investment thesis. Growth doesn’t appear to be a main reason for a buy decision for the company, at least in the near term.

What This Means For You

Are you a shareholder? Even though growth is relatively muted, since XRAY is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

ADVERTISEMENT

Are you a potential investor? If you’ve been keeping an eye on XRAY for a while, now might be the time to make a leap. Its future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy XRAY. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

So while earnings quality is important, it's equally important to consider the risks facing DENTSPLY SIRONA at this point in time. At Simply Wall St, we found 1 warning sign for DENTSPLY SIRONA and we think they deserve your attention.

If you are no longer interested in DENTSPLY SIRONA, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com